SAMIR SABBAG: Open Payments
NPI 1669620654 · MONTEREY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,527 in 146 payments from 11 companies in 2025. Trend: 2023 $6,893 · 2024 $1,260 · 2025 $2,527
Food & beverage: $2,304Education: $223
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $462 |
| Axsome Therapeutics, Inc. | 21 | $427 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $370 |
| Otsuka America Pharmaceutical, Inc. | 35 | $337 |
| Lundbeck LLC | 13 | $296 |
| Teva Pharmaceuticals USA, Inc. | 5 | $274 |
| Neurocrine BioSciences, Inc. | 8 | $154 |
| Alkermes, Inc. | 3 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
Products named: REXULTI, VRAYLAR, Auvelity, CAPLYTA, INGREZZA, TRINTELLIX, LYBALVI, UZEDY.
Industry payments across CA — which companies pay providers there.
